Last reviewed · How we verify
TM-601
At a glance
| Generic name | TM-601 |
|---|---|
| Also known as | Chlorotoxin (Synthetic) |
| Sponsor | TransMolecular |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (PHASE1)
- Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (PHASE1)
- Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma (PHASE1)
- A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma (PHASE1, PHASE2)
- A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma (PHASE1, PHASE2)
- 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma (PHASE2)
- 131-I-TM-601 Study in Adults With Solid Tumors (PHASE1)
- Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TM-601 CI brief — competitive landscape report
- TM-601 updates RSS · CI watch RSS
- TransMolecular portfolio CI